Discover and read the best of Twitter Threads about #covid4rheum
Most recents (1)
Hidroxychloroquine (HQ) basics for non-rheum in COVID-19:
- Increases endosomal pH, interferes with the glycosylation of cellular receptors of SARS-CoV2.
- In vitro activity in SARS-CoV and SARS-CoV2.
Proposed dosing (COVID-19): 400 mg bid 1 day➡️200 mg bid 4 days. Longer tx?
- Increases endosomal pH, interferes with the glycosylation of cellular receptors of SARS-CoV2.
- In vitro activity in SARS-CoV and SARS-CoV2.
Proposed dosing (COVID-19): 400 mg bid 1 day➡️200 mg bid 4 days. Longer tx?
Usually very well tolerated, most of adverse effects after months/years of therapy!
Better profile compared to chloroquine.
- Retinopathy. After long time-exposure, risk factors: > 5 mg/kg/day, renal insufficiency, tamoxifen use, obesity...
Not a problem for short term.
Better profile compared to chloroquine.
- Retinopathy. After long time-exposure, risk factors: > 5 mg/kg/day, renal insufficiency, tamoxifen use, obesity...
Not a problem for short term.
- Skin. Pruritus, rash, photosensibility...
- Myopathy. Rare. Usually long term use (1 year-10 years). Neuromyopathy (lisosomal changes, vacuoles in biopsy). Simmetrical weakness+/- sensitive symptoms.
- Myopathy. Rare. Usually long term use (1 year-10 years). Neuromyopathy (lisosomal changes, vacuoles in biopsy). Simmetrical weakness+/- sensitive symptoms.
